Barriers to effective implementation of guideline recommendations

American Journal of Medicine

Volumn 118, Issue 12 SUPPL., 2005, Pages 36-41

  Erhardt, Leif R ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Adherence; Cardiovascular disease; Hypercholesterolemia

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AWARENESS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL PRACTICE; CONFERENCE PAPER; DYSLIPIDEMIA; EUROPE; HEALTH CARE; HEALTH SURVEY; HUMAN; HYPERCHOLESTEROLEMIA; MOTIVATION; PATIENT EDUCATION; PERCEPTION; PHYSICAL CAPACITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; UNITED STATES;

EID: 28844506125     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.09.004     Document Type: Conference Paper

References (28)

1. European Society of Hypertension-European Society of Cardiology Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension J Hypertens 21 2003 1011 1053
2. G. De Backer, E. Ambrosioni, K. Borch-Johnsen Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice European guidelines on cardiovascular disease prevention in clinical practice Eur Heart J 24 2003 1601 1610
3. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
4. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 2003 US Dept of Health and Human Services, National Institutes of Health Bethesda, MD 1 52 NIH Publication No. 03-5233
5. T. Andrews, C. Ballantyne, J. Hsia, J.H. Kramer Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins Am J Med 111 2001 185 191
6. P. Jones, S. Kafonek, I. Laurora, D. Hunninghake Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) Am J Cardiol 81 1998 582 587
7. D.G. Karalis, A.M. Ross, R.M. Vacari, H. Zarren, R. Scott Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease Am J Cardiol 89 2002 667 671
8. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
9. F.M. Sacks, M.A. Pfeffer, L.A. Moye Cholesterol and Recurrent Events Trial investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009
10. J. Shepherd, S.M. Cobbe, I. Ford West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1307
11. The Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
12. J.R. Downs, M. Clearfield, S. Weis Air Force/Texas Coronary Atherosclerosis Prevention Study Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS/TexCAPS JAMA 279 1998 1615 1622
13. H.M. Colhoun, D.J. Betteridge, P.N. Durrington Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
14. P.S. Sever, B. Dahlof, N.R. Poulter ASCOT Investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) a multicentre randomised controlled trial Lancet 361 2003 1149 1158
15. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals a randomised placebo-controlled trial Lancet 360 2002 7 22
16. B. Neal, S. MacMahon, N. Chapman Blood Pressure Lowering Treatment Trialists' Collaboration Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs results of prospectively designed overviews of randomised trials Lancet 356 2000 1955 1964
17. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
18. American Heart Association Heart Disease and Stroke Statistics - 2003 Update 2002 American Heart Assoc iation Dallas, TX
19. EUROASPIRE (European Action on Secondary Prevention through Intervention to Reduce Events) Study Group EUROASPIRE: a European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results Eur Heart J 18 1997 1569 1582
20. EUROASPIRE (European Action on Secondary Prevention by Intervention to Reduce Events) I and II Group Clinical reality of coronary prevention guidelines a comparison of EUROASPIRE I and II in nine countries Lancet 357 2001 995 1001
21. T.A. Pearson, I. Laurora, H. Chu, S. Kafonek The Lipid Treatment Assessment Project (L-TAP) a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals Arch Intern Med 160 2000 459 467
22. M.J. Vale, M.V. Jelinek, J.D. Best How many patients with coronary heart disease are not achieving their risk-factor targets? Experience in Victoria 1996-1998 versus 1999-2000 Med J Aust 176 2002 211 215
23. A.I. Qureshi, M.F. Suri, L.R. Guterman, L.N. Hopkins Ineffective secondary prevention in survivors of cardiovascular events in the US population report from the Third National Health and Nutrition Examination Survey Arch Intern Med 161 2001 1621 1628
24. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) JAMA 269 1993 3015 3023
25. E.S. Ford, A.H. Mokdad, W.H. Giles, G.A. Mensah Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults findings from the National Health and Nutrition Examination Survey, 1999 to 2000 Circulation 107 2003 2185 2189
26. F.D. Hobbs, L. Erhardt Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey Fam Pract 19 2002 596 604
27. R.W. Grant, K.M. O'Leary, J.B. Weilburg, D.E. Singer, J.B. Meigs Impact of concurrent medication use on statin adherence and refill persistence Arch Intern Med 164 2004 2343 2348
28. L. Mosca, A.H. Linfante, E.J. Benjamin National study of physician awareness and adherence to cardiovascular disease prevention guidelines Circulation 111 2005 499 510